Mate, I don't care who is wrong or right, just that the large...

Mate, I don't care who is wrong or right, just that the large seller is out what ever their motivation!

On a side note was reading up intently last night on the stem cell situation in the US. It seems like there are near 1,000 clinics doing bone marrow and fat stem cells due to heightened demand in the US. The FDA has clamped down on the worse cowboys and that catches the headlines (three elderly women who had fat stem-cells and PRP for macular degeneration became blind at the hands of idiots) but I was reading an FDA release on the industry. They don't want to stifle innovation and indeed they want to advance the industry, but they want to protect patients from the cowboys too. There is a wealth of demand in the States by patients (hence the growth in small clinics blurring the regulatory line), but not a single strong entity giving formally proven stem-cell treatment (bar some immunotherapy and blood advancements).

“The FDA is committed to advancing the field of cell-based regenerative medicine. We’re implementing new policies to make it more efficient to safely develop these promising new technologies. At the same time, we’re also focusing more resources on enforcement when we see companies skirt safety measures and put patients at risk. In this case, the company’s failure to put in place appropriate safeguards may have led to serious blood infections in patients,” said FDA Commissioner Scott Gottlieb, M.D. “We remain committed to supporting the development of safe and effective cell-based regenerative medicine and advancing our comprehensive regenerative medicine policy framework. These efforts include our work to encourage manufacturers to engage with the FDA early so that we can provide guidance about any applicable regulatory requirements. Even though a few sponsors have come to us, we are discouraged by the overall lack of manufacturers wanting to interact with the agency in this enforcement discretion period".

OCC has already been well received by the FDA in regard to CelGro. I really am convinced, given OCC's already proven human trials with tennis elbow, a partnership with J&J and FDA endorsement, OCC could become effectively hold a bit of a monopoly in the future as an early significant player to market, whilst the FDA clamps down on unregulated small clinics - they have given them a 3 year window of discretion to get their acts in order, that ends this year.